KRAS Q61K

CI-VAR-00003567Explore in graph →NP_004976.2:p.Gln61LysNM_004985.4:c.181C>AClinVar 177777 CIViC 910 rs121913238

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm3
KRAS Q61K	Cetuximab	Predictive	B	Supports Resistance	3	submitted	EID2230 In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC) PMID 19603018 · Loupakis et al., 2009 · Open in CIViC	civic
KRAS Q61K	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3871 In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC) PMID 19603018 · Loupakis et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
177777	Pathogenic	criteria provided, single submitter	1	Non-small cell lung carcinoma; Colon adenocarcinoma; Thyroid cancer, nonmedullary, 1	germline/somatic	2	Aug 28, 2014	clinvar

Malignant Neoplasm2
KRAS Q61K	(oncogenic)	Oncogenic	D	Supports Oncogenicity	5	submitted	EID12976 KRAS p.Gln61Lys (NM_004985.5:c.181C>A) causes increased proliferation. PMID 3510078 · Der et al., 1986 · Open in CIViC	civic
KRAS Q61K OR KRAS G12S	Trametinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12455 Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. Lung adenocarcinoma cell lines A549 (KRAS G12S) and CALU-6 (KRAS Q61K) were sensitive w… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic

Unmapped disease1unmapped disease
KRAS Q61K	(functional)	Functional	D	Supports Gain Of Function	5	submitted	EID12975 KRAS p.Gln61Lys (NM_004985.5:c.181C>A) causes decreased GTPase activity, and based on BRAF-RBD co-IP assay increased BRAF binding affinity. PMID 26037647 · Hunter et al., 2015 · Open in CIViC	civic